For instance, although the PD‐L1 expression is the exclusive biomarker approved by FDA for applying ICIs for LUAD population and long‐lasting beneficial responses have appeared in the PD‐L1‐positive NSCLC sufferers treated with PD‐L1 inhibitors, only a few percentiles of patients have been benefited from this immunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.